Terms used across this site. Toggle between technical definitions and plain-language explanations.
Unit of absolute pressure. 1 ATA equals standard atmospheric pressure at sea level (101.325 kPa / 760 mmHg). Hyperbaric pressures are expressed in ATA to include ambient pressure in the measurement—so 1.5 ATA means 50% above sea-level pressure. Dissolved gas behavior follows partial pressure, making ATA the natural unit for calculating tissue oxygenation via Henry's Law.
A way to measure pressure. 1 ATA is normal air pressure at sea level. A home HBOT chamber at 1.5 ATA means the pressure inside is 50% higher than the air around you right now.
The liquid matrix of blood—water, electrolytes, proteins, and dissolved gases—comprising roughly 55% of total blood volume. Under hyperbaric conditions, O2 dissolves directly into plasma following Henry's Law, bypassing hemoglobin transport entirely. This dissolved fraction is the sole mechanism of HBOT's oxygen delivery advantage, since hemoglobin is already 97–99% saturated at normoxia.
The liquid part of your blood (about 55% of it). During HBOT, extra oxygen dissolves directly into this liquid, which can flow into tight spaces that red blood cells can't reach.
Iron-containing metalloprotein in erythrocytes responsible for ~98.5% of oxygen transport under normal conditions. Each hemoglobin molecule binds up to four O2 molecules cooperatively. At sea level, arterial hemoglobin saturation (SpO2) is already 97–99%—there's essentially no room to load more. HBOT's benefit comes entirely from plasma-dissolved O2, not from increasing hemoglobin saturation.
The protein in red blood cells that carries oxygen. It's already carrying as much as it can at sea level—basically maxed out. That's why HBOT works through a different route: dissolving oxygen into the liquid part of your blood instead.
Extracellular fluid occupying the spaces between cells, constituting roughly 15% of body weight. Nutrients and waste products exchange between capillaries and cells through this compartment. Plasma-dissolved O2 diffuses freely into ISF, reaching tissue that hemoglobin-bound oxygen cannot access when capillaries are damaged, compressed, or absent. This is the primary therapeutic target of HBOT in ischemic and edematous tissues.
The fluid that surrounds every cell in your body. Dissolved oxygen from HBOT can seep into this fluid and reach cells that aren't getting enough oxygen because nearby blood vessels are damaged or blocked.
Pressure-swing adsorption device that separates O2 from ambient air using zeolite molecular sieves, outputting approximately 93% (±3%) oxygen at flow rates up to 10 LPM. At 1.5 ATA, a 10 LPM concentrator produces sufficient O2 to saturate the chamber environment. Above 1.5 ATA the concentrator becomes the limiting factor—pressure rises but ppO2 doesn't proportionally increase without switching to 100% cylinder O2.
A machine that pulls oxygen out of room air and concentrates it to about 93%. Paired with a home chamber at 1.5 ATA, it delivers the full oxygen benefit. Push the pressure higher and the machine can't keep up—you'd need medical-grade oxygen tanks instead.
Chemically reactive molecules containing oxygen—superoxide (O2−), hydrogen peroxide (H2O2), hydroxyl radicals. At controlled levels during HBOT, ROS act as signaling molecules that upregulate antioxidant enzymes (SOD, catalase, GPx), DNA repair pathways, and cytoprotective gene expression. This is the hormetic trigger upstream of most HBOT mechanisms. Identical ROS kinetic profiles have been measured at 1.4 and 2.5 ATA.
Molecules your body makes when it gets a burst of extra oxygen. In small, controlled amounts, they act as an alarm signal that tells your cells to turn on repair and defense programs. The same signal fires at home-chamber pressure as in clinical chambers.
Dose-response phenomenon where low-level exposure to a stressor triggers adaptive responses that exceed the magnitude of the original insult. The biological basis for exercise adaptation, heat/cold conditioning, and HBOT. Hyperoxic hormesis via controlled ROS generation activates Nrf2-mediated antioxidant pathways, heat shock proteins, and DNA repair—producing a net protective effect despite the transient oxidative challenge.
The principle that a small, controlled stress makes your body stronger than before. Exercise works this way—you stress muscles and they grow back stronger. HBOT applies the same principle with oxygen: a controlled burst triggers your body to build up its defenses.
Master transcription factor that activates over 100 downstream genes involved in angiogenesis, erythropoiesis, glucose metabolism, and cell survival. Normally degraded in the presence of oxygen via prolyl hydroxylase. The HBOT paradox: repeated hyperoxia-normoxia cycling depletes intracellular oxygen scavengers, so when the session ends, relative hypoxia triggers HIF-1α stabilization and nuclear translocation. This drives VEGF, EPO, SDF-1, and sirtuin expression between sessions.
A protein that acts as a master switch for building oxygen infrastructure—new blood vessels, more red blood cells, tissue repair. After each HBOT session, your body senses the oxygen drop-off and activates this switch. That's why the benefits build between sessions, not just during them.
A signaling protein produced by cells in response to HIF-1α activation that stimulates vasculogenesis and angiogenesis. VEGF binds to receptors on endothelial cells, triggering proliferation, migration, and tube formation. HBOT elevates serum VEGF via the hyperoxic-hypoxic paradox. Works in concert with PDGF and FGF for vessel stabilization and maturation.
A protein that tells your body to grow new blood vessels. HBOT raises VEGF levels, which leads to new capillary formation in areas that need better circulation. Once built, these vessels are permanent infrastructure.
The physiological process of new capillary formation from pre-existing vasculature. Involves endothelial cell activation, extracellular matrix degradation, cell migration, proliferation, and tube formation. HBOT drives angiogenesis through the HIF-1α/VEGF/SDF-1 signaling cascade. Clinically documented in diabetic wound healing models and crush injury RCTs. The resulting vascular remodeling persists after treatment cessation.
Growing new tiny blood vessels from existing ones. HBOT triggers this process, improving circulation to areas that were oxygen-starved. The new vessels stay after you stop treatment—it's permanent construction, not a temporary boost.
An enzyme in bone marrow endothelial cells that catalyzes nitric oxide (NO) production from L-arginine. Under hyperoxic conditions, eNOS activation triggers a cascade: NO → MMP-9 activation → cleavage of membrane-bound Kit ligand → release of CD34+ progenitor cells from their bone marrow niche into peripheral circulation. This is the mechanism by which HBOT mobilizes stem cells.
An enzyme in your bone marrow that responds to HBOT by producing a signal molecule (nitric oxide). This signal unlocks stem cells from the bone marrow, releasing them into your bloodstream to find and repair damaged tissue throughout your body.
Hematopoietic progenitor cells expressing the CD34 surface glycoprotein, capable of differentiating into endothelial cells, smooth muscle, and other tissue types. Reside in bone marrow and are mobilized into circulation via eNOS/MMP-9 signaling during HBOT. Home to damaged tissue via SDF-1 chemotaxis. A single HBOT session at 2.0 ATA doubles circulating CD34+ counts; dose-response is continuous, with measurable mobilization even at 1.27 ATA with air.
Your body's repair cells, stored in bone marrow. They can travel through your bloodstream to damaged areas and become the type of cell needed for repair. HBOT releases more of them into circulation—a single session doubles the count. Even mild pressure works; it's a dial, not a switch.
Repetitive nucleotide sequences (TTAGGG in humans) capping chromosome ends, preventing degradation and end-to-end fusion during replication. Telomeres shorten with each cell division due to the end-replication problem; length is a validated biomarker of biological aging. The Efrati 2020 trial demonstrated 20–38% telomere lengthening across immune cell subtypes after 60 HBOT sessions at 2.0 ATA/100% O2. Mechanism likely involves telomerase upregulation via HIF-1α.
Protective caps on the ends of your DNA, like the plastic tips on shoelaces. They get shorter each time a cell divides, and their length is one of the best-known markers of biological age. A clinical trial showed HBOT lengthened them by 20–38%—but only at clinical pressure (2.0 ATA), not yet proven at home levels.
Cells that have exited the cell cycle irreversibly (replicative arrest) but resist apoptosis and remain metabolically active. They accumulate with age and secrete SASP—a cocktail of pro-inflammatory cytokines, chemokines, and matrix metalloproteinases—driving chronic low-grade inflammation ("inflammaging"). The Efrati trial showed 11–37% reduction in senescent T cell populations after 60 HBOT sessions at 2.0 ATA, likely via immune-mediated clearance rather than direct senolysis.
Cells that stop doing their job but refuse to die. They sit in your tissues and leak inflammatory molecules that damage everything around them. HBOT at clinical pressure reduced these cells by 11–37% in a human trial—something the pharmaceutical industry is spending billions trying to achieve with drugs.
The pro-inflammatory secretome of senescent cells, comprising IL-6, IL-8, TNF-α, MCP-1, VEGF, and matrix metalloproteinases (MMPs) among others. SASP drives paracrine senescence (spreading the senescent phenotype to neighboring cells), extracellular matrix degradation, and chronic tissue inflammation. It's a primary driver of age-related pathology and a key target of both senolytic drugs and HBOT-mediated clearance protocols.
The inflammatory cocktail that zombie cells (senescent cells) constantly leak into surrounding tissue. It causes chronic inflammation, damages nearby healthy cells, and can even turn them into zombie cells too. Reducing the source cells is the goal—stop the leak by clearing the leakers.
A family of transcription factors (p50/p65 heterodimer being canonical) that regulate expression of genes involved in inflammation, immune response, and cell survival. Normally sequestered in the cytoplasm by IκB inhibitor proteins. Activation leads to translocation to the nucleus and transcription of TNF-α, IL-1β, IL-6, COX-2, and iNOS. HBOT suppresses NF-κB signaling, reducing downstream inflammatory mediators. This suppression operates wherever hyperoxia is achieved, including at 1.4–1.5 ATA.
The master switch for inflammation genes. When it's on, your body produces pain, swelling, and fatigue signals. HBOT turns this switch down, reducing chronic inflammation. This works at home-chamber pressure—anywhere extra oxygen reaches, the anti-inflammatory effect follows.
A family of NAD+-dependent deacetylases involved in DNA repair, mitochondrial biogenesis, metabolic regulation, and stress resistance. SIRT1 and SIRT3 are the most studied in longevity contexts. HBOT upregulates sirtuin expression via the HIF-1α pathway. Sirtuins are also the downstream target of caloric restriction and NAD+ precursor supplementation (NMN/NR), placing HBOT in the same signaling network as these established longevity interventions.
A family of proteins that manage cellular repair and longevity. They're the same proteins activated by calorie restriction and NAD+ supplements. HBOT activates them through the HIF-1α pathway, linking it to the same repair network as other longevity interventions.
The brain's capacity to reorganize synaptic connections, form new neural pathways, and modulate existing circuitry in response to experience, injury, or environmental change. HBOT promotes neuroplasticity through multiple converging mechanisms: direct oxygenation of hypoperfused brain tissue, cerebral angiogenesis, reduction of neuroinflammation via microglial suppression, and upregulation of neurotrophic factors (BDNF, NGF). The 2025 RCT at 1.5 ATA demonstrated measurable cognitive improvement consistent with enhanced neuroplastic processes.
Your brain's ability to rewire itself—forming new connections and strengthening existing ones. HBOT supports this by getting more oxygen to brain tissue, growing new blood vessels in the brain, and reducing neuroinflammation. A clinical trial at home-chamber pressure showed real cognitive improvements from this process.
At constant temperature, the amount of gas dissolved in a liquid is directly proportional to the partial pressure of that gas above the liquid. Formally: C = kH · P, where C is dissolved concentration, kH is Henry's constant, and P is partial pressure. This is the physics underlying all of HBOT: doubling the pressure above blood plasma doubles the dissolved O2. It's why the jump from 1.0 to 1.5 ATA produces a 10x dissolved O2 increase when paired with concentrated oxygen.
A physics law: more pressure above a liquid means more gas dissolves into it. This is why HBOT works. Increase the air pressure, add concentrated oxygen, and vastly more oxygen dissolves into your blood plasma. Simple physics, large biological effect.
Tissue injury caused by pressure differentials between gas-filled spaces and surrounding tissue during pressurization or depressurization. In HBOT, the primary risk is middle ear barotrauma (inability to equalize Eustachian tube pressure), followed by sinus barotrauma. Incidence varies by study (2–10% for ear discomfort); serious barotrauma (tympanic membrane rupture) is rare with proper equalization technique and controlled pressurization rates. Essentially a non-issue at 1.5 ATA with gradual pressure changes.
Pressure-related tissue damage, mostly affecting the ears. Same thing that happens on an airplane if you can't equalize, but at 1.5 ATA it's milder. Learn to equalize your ears (swallow, yawn, or pinch-and-blow) and pressurize slowly. Serious injury is very rare.
Transient myopic shift caused by oxidative changes to the crystalline lens, altering its refractive index. Reported in some patients undergoing extended HBOT protocols (typically 20+ sessions). The effect is fully reversible upon cessation of treatment, usually resolving within 2–8 weeks. More common at higher pressures and with 100% O2; less likely at 1.5 ATA with 93% concentrator output. Does not represent structural damage to the eye.
A temporary change in vision (things far away get slightly blurry) that some people experience during long HBOT protocols. It goes away within a few weeks after stopping or reducing sessions. It's a lens chemistry change, not eye damage. Less common at home-chamber pressure.
The effective pressure exerted by oxygen in a gas mixture, calculated as total pressure multiplied by oxygen fraction (ppO2 = Ptotal × FiO2). At sea level breathing room air: 1.0 × 0.21 = 0.21 ATA. At 1.5 ATA with a 93% concentrator: 1.5 × 0.93 = 1.395 ATA. This is the number that determines dissolved O2 via Henry's Law and the number that determines oxygen toxicity thresholds. CNS toxicity risk begins above approximately 1.6 ATA ppO2; home setups at 1.5 ATA/93% stay well below this.
How much oxygen pressure your body actually experiences, combining chamber pressure with oxygen concentration. A home setup (1.5 ATA, 93% oxygen) produces a ppO2 of about 1.4—well below the ~1.6 threshold where oxygen toxicity becomes a concern. This is why home HBOT has such wide safety margins.
Elevated tissue oxygen tension above physiological normoxia. The controlled hyperoxic state during HBOT is the upstream trigger for ROS signaling, NF-κB suppression, eNOS activation, and—via the hyperoxic-hypoxic paradox—HIF-1α stabilization between sessions. Identical ROS kinetics at 1.4 ATA and 2.5 ATA confirm that mild hyperoxia is sufficient to activate these cascades.
Having more oxygen in your tissues than normal. This is what HBOT creates—a controlled burst of extra oxygen that triggers your body's repair programs. The key insight is that even mild hyperoxia (home-chamber levels) activates the same signals as intense clinical hyperoxia.
Normal physiological oxygen tension (~100 mmHg arterial, ~40 mmHg venous). Return to normoxia after an HBOT session depletes residual antioxidant scavengers, creating relative tissue hypoxia that triggers HIF-1α stabilization. This hyperoxia–normoxia cycling is the mechanism behind HBOT's between-session benefits: VEGF production, stem cell mobilization, and sirtuin upregulation all occur during the normoxic recovery phase.
Normal oxygen levels. When you leave the chamber and oxygen drops back to normal, your body interprets this as “not enough oxygen” and switches on programs to build more capacity—new blood vessels, more red blood cells, tissue repair. The benefits build between sessions, not just during them.
The smallest blood vessels (5–10 μm diameter), consisting of a single layer of endothelial cells. Site of all gas, nutrient, and waste exchange between blood and tissue. When capillaries are damaged, compressed, or absent, hemoglobin-bound oxygen cannot reach tissue—but plasma-dissolved O2 from HBOT can diffuse through interstitial fluid to bridge the gap. HBOT also grows new capillaries via VEGF-driven angiogenesis.
The tiniest blood vessels in your body, where oxygen actually passes from blood into tissue. When these are damaged or blocked, cells starve for oxygen. HBOT bypasses damaged capillaries by dissolving oxygen directly into blood plasma, and also grows new capillaries over time.
Small signaling proteins (<40 kDa) secreted by immune cells to mediate inflammatory and immune responses. Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) drive acute and chronic inflammation. Anti-inflammatory cytokines (IL-10, TGF-β) resolve it. HBOT suppresses pro-inflammatory cytokine production via NF-κB inhibition while promoting anti-inflammatory signaling through macrophage M1→M2 polarization.
Signaling molecules that control your immune and inflammatory responses. Some cause inflammation (pain, swelling, fatigue), others resolve it. HBOT shifts the balance toward the anti-inflammatory ones by turning down the master inflammation switch and reprogramming immune cells toward repair mode.
Innate immune phagocytes existing in two primary polarization states. M1 macrophages produce pro-inflammatory cytokines (TNF-α, IL-6) and generate reactive oxygen species for pathogen killing. M2 macrophages secrete anti-inflammatory cytokines (IL-10, TGF-β) and promote tissue remodeling, angiogenesis, and wound healing. HBOT promotes M1→M2 polarization, shifting the immune environment from inflammatory to reparative.
Immune cells that operate in two modes: attack mode (M1) that causes inflammation, and repair mode (M2) that heals tissue. HBOT shifts them from attack to repair mode—one of the ways it reduces chronic inflammation while promoting healing.
The production of red blood cells (erythrocytes) in bone marrow. Regulated by erythropoietin (EPO), which is transcriptionally controlled by HIF-1α. HBOT drives erythropoiesis via the hyperoxic-hypoxic paradox: repeated hyperoxia–normoxia cycling stabilizes HIF-1α between sessions, increasing EPO and stimulating red blood cell production.
Your body's process of making new red blood cells. HBOT stimulates this through the same pathway that builds new blood vessels—the HIF-1α switch activated between sessions tells your bone marrow to produce more oxygen-carrying cells.
A cartilaginous and bony tube (~35 mm) connecting the middle ear to the nasopharynx. Normally closed, it opens during swallowing, yawning, or the Valsalva maneuver to equalize pressure across the tympanic membrane. Dysfunction during HBOT pressurization is the primary cause of middle ear barotrauma. Technique develops quickly—most users equalize reliably within five to ten sessions.
The tube connecting your middle ear to your throat. It opens when you swallow, yawn, or pinch your nose and blow gently. Learning to open it reliably is the main skill for comfortable HBOT sessions—it prevents the ear pressure you feel during pressurization.
Pathological accumulation of excess fluid in interstitial tissue spaces. Causes include increased capillary permeability, lymphatic obstruction, and oncotic pressure imbalance. HBOT reduces edema through hyperoxic vasoconstriction (reducing capillary hydrostatic pressure) while simultaneously increasing tissue oxygenation via plasma-dissolved O2—a paradoxical combination unique to hyperbaric therapy.
Swelling from excess fluid trapped in tissues. HBOT reduces it by constricting blood vessels (which lowers the fluid pressure leaking out) while still delivering more oxygen through the dissolved-in-plasma route. One of the few therapies that reduces swelling and increases oxygenation simultaneously.
Insufficient blood supply to tissue, resulting in oxygen and nutrient deprivation. Causes range from atherosclerosis to traumatic vessel damage. Plasma-dissolved O2 from HBOT can reach ischemic tissue by diffusing through interstitial fluid, independent of capillary blood flow. This is a primary therapeutic target of HBOT—bridging the oxygen gap while angiogenesis builds new vasculature.
When tissue doesn't get enough blood flow and starves for oxygen—from blocked or damaged blood vessels. HBOT's dissolved oxygen can seep through surrounding fluid to reach these starved areas while the body grows new blood vessels to permanently fix the supply problem.
Double-membrane organelles responsible for aerobic ATP production via oxidative phosphorylation. Oxygen is the terminal electron acceptor in the electron transport chain—mitochondrial function is directly dependent on O2 availability. HBOT supports mitochondrial metabolic recovery in hypoperfused tissue and stimulates mitochondrial biogenesis via sirtuin (SIRT1/SIRT3) and PGC-1α pathways activated during hyperoxia–normoxia cycling.
Your cells' power plants. They use oxygen to produce the energy (ATP) that runs everything in your body. HBOT gives them more fuel to work with and triggers your body to build more mitochondria over time—literally increasing your cells' energy-producing capacity.
An agent that selectively induces apoptosis in senescent cells. Pharmacological senolytics (dasatinib + quercetin, navitoclax, fisetin) target anti-apoptotic pathways that senescent cells depend on for survival. HBOT achieves senolytic-like clearance through a different mechanism—enhanced immune surveillance via reactivated T cells and macrophage-mediated clearance rather than direct pharmacological killing.
Anything that clears out zombie (senescent) cells. Drug companies are spending billions developing pills that do this. HBOT appears to achieve similar results through a different route—boosting your immune system's ability to identify and clear these dysfunctional cells naturally.
A generalized seizure involving two phases: tonic (sustained skeletal muscle contraction, 10–20 seconds) followed by clonic (rhythmic jerking, 30–60 seconds). In the context of HBOT, this is the Paul Bert effect—CNS oxygen toxicity from ppO2 exceeding ~1.6–1.7 ATA. Self-limiting: seizure terminates when hyperoxic exposure ends. Incidence at clinical pressure is ~1 in 634 treatments. Essentially impossible at home-chamber ppO2 (~1.4 ATA).
A type of seizure (stiffening then jerking) that can occur from too much oxygen. At clinical pressure, the risk is about 1 in 634 treatments, and it stops as soon as the oxygen is reduced. At home-chamber pressure, the oxygen level stays well below the seizure threshold—the risk is essentially zero.
Presence of air in the pleural space between the lung and chest wall, causing partial or complete lung collapse. An absolute contraindication for HBOT: during depressurization, trapped pleural air expands (Boyle's Law), potentially converting a simple pneumothorax into a tension pneumothorax—a life-threatening emergency requiring immediate needle decompression. Must be fully resolved before initiating any hyperbaric protocol.
A collapsed lung caused by air leaking into the space around the lung. This is one of the few absolute “do not use HBOT” conditions—pressure changes in the chamber can make a collapsed lung dramatically worse. Must be fully treated before starting any HBOT protocol.